JCR Pharmaceuticals Co., Ltd. (JP:4552) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
JCR Pharmaceuticals Co., Ltd. reported a significant decline in their financial performance for the first half of FY2024, with net sales dropping by 31.4% and a net loss per share compared to the same period last year. Despite maintaining dividend forecasts, the company revealed changes in its subsidiary structure, excluding Mycenax Biotech Inc. from consolidation.
For further insights into JP:4552 stock, check out TipRanks’ Stock Analysis page.